JP2023103205A5 - - Google Patents

Download PDF

Info

Publication number
JP2023103205A5
JP2023103205A5 JP2023060583A JP2023060583A JP2023103205A5 JP 2023103205 A5 JP2023103205 A5 JP 2023103205A5 JP 2023060583 A JP2023060583 A JP 2023060583A JP 2023060583 A JP2023060583 A JP 2023060583A JP 2023103205 A5 JP2023103205 A5 JP 2023103205A5
Authority
JP
Japan
Prior art keywords
cancer
independently
compound according
butyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023060583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023103205A (ja
Filing date
Publication date
Priority claimed from JP2018567684A external-priority patent/JP7317505B2/ja
Application filed filed Critical
Publication of JP2023103205A publication Critical patent/JP2023103205A/ja
Publication of JP2023103205A5 publication Critical patent/JP2023103205A5/ja
Priority to JP2025116381A priority Critical patent/JP2025148450A/ja
Pending legal-status Critical Current

Links

JP2023060583A 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物 Pending JP2023103205A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116381A JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353735P 2016-06-23 2016-06-23
US62/353,735 2016-06-23
JP2018567684A JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018567684A Division JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116381A Division JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Publications (2)

Publication Number Publication Date
JP2023103205A JP2023103205A (ja) 2023-07-26
JP2023103205A5 true JP2023103205A5 (https=) 2023-10-18

Family

ID=60675799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018567684A Active JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物
JP2023060583A Pending JP2023103205A (ja) 2016-06-23 2023-04-04 腫瘍死滅に影響する二重標的構築物
JP2025116381A Pending JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018567684A Active JP7317505B2 (ja) 2016-06-23 2017-06-22 腫瘍死滅に影響する二重標的構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116381A Pending JP2025148450A (ja) 2016-06-23 2025-07-10 腫瘍死滅に影響する二重標的構築物

Country Status (10)

Country Link
US (4) US10179117B2 (https=)
EP (2) EP4520745A3 (https=)
JP (3) JP7317505B2 (https=)
KR (2) KR102864909B1 (https=)
CN (2) CN109843339B (https=)
AU (2) AU2017281364B2 (https=)
CA (1) CA3028978A1 (https=)
IL (1) IL263863B (https=)
SG (1) SG11201811482YA (https=)
WO (1) WO2017223357A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2020139012A1 (ko) * 2018-12-27 2020-07-02 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
CA3199581A1 (en) * 2020-11-30 2022-06-02 Neil H. Bander Cancer immunotherapies to promote hyperacute rejection
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
CN115448856B (zh) * 2022-09-30 2023-09-22 北京师范大学 一种用于靶向PSMA的EuK二聚体化合物、衍生物及其应用
WO2025213026A1 (en) * 2024-04-04 2025-10-09 Lantheus Medical Imaging, Inc. Astatine-211-labelled psma-binding compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
WO2006091796A2 (en) 2005-02-22 2006-08-31 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
PT2318366T (pt) * 2008-08-01 2017-08-02 Univ Johns Hopkins Agentes de ligação a psma e suas utilizações
WO2010032248A2 (en) 2008-09-17 2010-03-25 Yeda Research And Development Co. Ltd. Multifunctional albumin conjugates
JP2012511024A (ja) * 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のca−ix特異性放射性医薬品
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
CN103732595B (zh) 2011-08-17 2017-02-08 默克及其合伙人公司 叶酸的白蛋白‑结合实体缀合物
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10140408B2 (en) 2015-09-04 2018-11-27 Qualcomm Incorporated Selectively encrypting content for distribution from a receiver device to a companion device
US20200231614A1 (en) * 2015-10-22 2020-07-23 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
EP3609541A4 (en) 2017-04-05 2021-04-07 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
US11400165B2 (en) 2017-11-04 2022-08-02 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
SG11202109761TA (en) 2019-04-03 2021-10-28 Tarveda Therapeutics Inc Hsp90-binding conjugates and formulations thereof
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
CA3070610A1 (en) 2020-01-31 2021-07-31 Humphrey FONGE Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
US12151004B2 (en) 2020-01-31 2024-11-26 University Of Saskatchewan Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
US20220143228A1 (en) 2020-10-22 2022-05-12 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
UY39510A (es) 2020-11-10 2022-05-31 Janssen Biotech Inc Compuestos macrocíclicos y métodos para usarlos
JP2024503924A (ja) 2021-01-27 2024-01-29 ヤンセン バイオテツク,インコーポレーテツド カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用
GEAP202316335A (en) 2021-02-01 2023-10-10 Bayer Ag Multimeric chelator compounds for use in targeted radiotherapy
US20230011134A1 (en) 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
KR20240053607A (ko) 2021-08-27 2024-04-24 얀센 바이오테크 인코포레이티드 항-psma 방사성 접합체 및 이의 용도
AU2022333321A1 (en) 2021-08-27 2024-04-11 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
CN118317957A (zh) 2021-09-29 2024-07-09 墨尔本大学 在靶向放射疗法应用中作为配体的含大环的化合物和其放射性标记的络合物
CA3240194A1 (en) 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
JP2024543046A (ja) 2021-11-09 2024-11-19 ヤンセン バイオテツク,インコーポレーテツド 大環状化合物及びその診断上の使用

Similar Documents

Publication Publication Date Title
JP2023103205A5 (https=)
JP2017095457A5 (https=)
JP2019535744A5 (https=)
JP2019535746A5 (https=)
JP2024543967A5 (https=)
JP2022512900A5 (https=)
JP2022071077A5 (https=)
JP2020517616A5 (https=)
JP2022547952A5 (https=)
JP2023539715A5 (https=)
JP2024530495A5 (https=)
IL266563B (en) Heterocyclic compounds useful as pdk1 inhibitors
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
NZ758176A (en) Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
JP2023545096A5 (https=)
JP2021534168A5 (https=)
JP2005500266A5 (https=)
JP2024506612A5 (https=)
JP2017509682A5 (https=)
JP2013166763A5 (https=)
RU2020113749A (ru) Аналоги таиланстатина
JP2021523169A5 (https=)
JP2020534300A5 (https=)
JP2009503110A5 (https=)